The clinical success of cancer immune checkpoint blockade (ICB) has refocused attention
on tumor-infiltrating lymphocytes (TILs) across cancer types. The outcome of immune …

Abstract Endometrial cancer accounts for~ 76,000 deaths among women each year
worldwide. Disease mortality and the increasing number of new diagnoses make …

Pathogenic somatic missense mutations within the DNA polymerase epsilon (POLE)
exonuclease domain define the important subtype of ultramutated tumours ('POLE …

Immune checkpoint blockade targeting PD-1/PD-L1 has promising therapeutic efficacy in a
variety of tumors, but resistance during treatment is a major issue. In this review, we describe …

Histopathological evaluation including subty** and grading is the current cornerstone for
endometrial cancer (EC) classification. This provides clinicians with prognostic information …

BACKGROUND Endometrial cancers (ECs) with somatic mutations in DNA polymerase
epsilon (POLE) are characterized by unfavorable pathological features, which prompt …

Simple Summary Tumor mutational burden (TMB) represents the number of mutations per
megabase (muts/Mb) harbored by tumor cells in a given neoplasm, and can be determined …

Endometrial cancer is a clinically heterogeneous disease and it is becoming increasingly
clear that this heterogeneity may be a function of the diversity of the underlying molecular …

Cancer immunotherapy has experienced remarkable advances in recent years. Striking
clinical responses have been achieved for several types of solid cancers (eg melanoma …

Endometrial cancer is the most commonly diagnosed gynecologic malignancy in the United
States. Endometrioid endometrial carcinomas constitute approximately 85% of newly …